Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 308
Filter
1.
Cell Stem Cell ; 29(3): 434-448.e5, 2022 03 03.
Article in English | MEDLINE | ID: mdl-35180398

ABSTRACT

Midbrain dopamine (mDA) neurons can be replaced in patients with Parkinson's disease (PD) in order to provide long-term improvement in motor functions. The limited capacity for long-distance axonal growth in the adult brain means that cells are transplanted ectopically, into the striatal target. As a consequence, several mDA pathways are not re-instated, which may underlie the incomplete restoration of motor function in patients. Here, we show that viral delivery of GDNF to the striatum, in conjunction with homotopic transplantation of human pluripotent stem-cell-derived mDA neurons, recapitulates brain-wide mDA target innervation. The grafts provided re-instatement of striatal dopamine levels and correction of motor function and also connectivity with additional mDA target nuclei not well innervated by ectopic grafts. These results demonstrate the remarkable capacity for achieving functional and anatomically precise reconstruction of long-distance circuitry in the adult brain by matching appropriate growth-factor signaling to grafting of specific cell types.


Subject(s)
Dopamine , Pluripotent Stem Cells , Adult , Dopamine/metabolism , Genetic Therapy , Glial Cell Line-Derived Neurotrophic Factor/metabolism , Humans , Mesencephalon/metabolism , Pluripotent Stem Cells/metabolism , Substantia Nigra/metabolism , Substantia Nigra/transplantation
2.
J Tissue Eng Regen Med ; 12(7): 1702-1716, 2018 07.
Article in English | MEDLINE | ID: mdl-29766664

ABSTRACT

The classic motor deficits of Parkinson's disease are caused by degeneration of dopaminergic neurons in the substantia nigra pars compacta, resulting in the loss of their long-distance axonal projections that modulate the striatum. Current treatments only minimize the symptoms of this disconnection as there is no approach capable of replacing the nigrostriatal pathway. We are applying microtissue engineering techniques to create living, implantable constructs that mimic the architecture and function of the nigrostriatal pathway. These constructs consist of dopaminergic neurons with long axonal tracts encased within hydrogel microcolumns. Microcolumns were seeded with dopaminergic neuronal aggregates, while lumen extracellular matrix, growth factors, and end targets were varied to optimize cytoarchitecture. We found a 10-fold increase in axonal outgrowth from aggregates versus dissociated neurons, resulting in remarkable axonal lengths of over 6 mm by 14 days and 9 mm by 28 days in vitro. Axonal extension was also dependent upon lumen extracellular matrix, but did not depend on growth factor enrichment or neuronal end target presence. Evoked dopamine release was measured via fast scan cyclic voltammetry and synapse formation with striatal neurons was observed in vitro. Constructs were microinjected to span the nigrostriatal pathway in rats, revealing survival of implanted neurons while maintaining their axonal projections within the microcolumn. Lastly, these constructs were generated with dopaminergic neurons differentiated from human embryonic stem cells. This strategy may improve Parkinson's disease treatment by simultaneously replacing lost dopaminergic neurons in the substantia nigra and reconstructing their long-projecting axonal tracts to the striatum.


Subject(s)
Brain Tissue Transplantation , Corpus Striatum , Dopaminergic Neurons , Parkinson Disease , Substantia Nigra , Tissue Engineering , Animals , Cell Line , Corpus Striatum/metabolism , Corpus Striatum/pathology , Corpus Striatum/transplantation , Dopaminergic Neurons/metabolism , Dopaminergic Neurons/pathology , Dopaminergic Neurons/transplantation , Female , Heterografts , Humans , Male , Parkinson Disease/metabolism , Parkinson Disease/pathology , Parkinson Disease/surgery , Rats , Rats, Sprague-Dawley , Substantia Nigra/metabolism , Substantia Nigra/pathology , Substantia Nigra/transplantation
3.
Stem Cells Dev ; 27(14): 995-1005, 2018 07 15.
Article in English | MEDLINE | ID: mdl-29562865

ABSTRACT

Glial cell line-derived neurotrophic factor (GDNF) exhibits potent neuroprotective properties in preclinical models of Parkinson's disease (PD), but challenges in GDNF delivery have been reported from clinical trials. To address this barrier, we developed a hematopoietic stem cell transplantation-based macrophage-mediated GDNF therapy platform. Here, we introduced a regulatable lentiviral vector (LV-MSP-Tet-Off-hGDNF) to allow the expression of human GDNF (hGDNF) to be adjusted or stopped by oral administration of doxycycline (Dox). C57BL/6J mice were lethally irradiated with head protection and then transplanted with syngeneic bone marrow cells transduced with either the hGDNF-expressing vector or a corresponding GFP-expressing vector, LV-MSP-Tet-Off-GFP. Suppression of vector gene expression was achieved through administration of Dox in drinking water. To create a toxin-induced Parkinsonian model, mice were injected in two cycles with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) to yield nigral cell/striatal dopamine loss and behavioral deficits. During the presence of Dox in the drinking water, plasma GDNF was at a basal level, whereas during the absence of Dox, plasma GDNF was significantly elevated, indicating reliable regulation of therapeutic gene expression. Midbrain GDNF levels were altered in parallel, although these did not return completely to basal levels during the periods of Dox withdrawal. Motor activities of the MPTP-Tet-off-hGDNF group were comparable to those of the Tet-off-GFP (subject to no MPTP treatment) group, but substantially better than those of the MPTP-Tet-off-GFP group. Interestingly, the improvement in motor activities was sustained during the Dox-withdrawn periods in MPTP-Tet-off-hGDNF animals. Neuroprotection by therapeutic GDNF expression was further evidenced by significant amelioration of nigral tyrosine hydroxylase loss after both the first and second MPTP treatment cycles. These data suggest that neurotrophic factor expression can be upregulated to achieve efficacy or downregulated in case of off-target effects or adverse events, a feature that may eventually increase the acceptance of this potentially neuroprotective/disease-modifying PD therapy.


Subject(s)
Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells , Parkinson Disease, Secondary/therapy , Parkinson Disease/therapy , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/adverse effects , Animals , Cell Differentiation/drug effects , Corpus Striatum/drug effects , Corpus Striatum/pathology , Corpus Striatum/transplantation , Disease Models, Animal , Dopamine/metabolism , Gene Expression Regulation, Developmental , Genetic Vectors/therapeutic use , Humans , Mice , Parkinson Disease/genetics , Parkinson Disease/physiopathology , Parkinson Disease, Secondary/chemically induced , Parkinson Disease, Secondary/physiopathology , Substantia Nigra/drug effects , Substantia Nigra/pathology , Substantia Nigra/transplantation
4.
Rev Neurol (Paris) ; 169(11): 838-43, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24112517

ABSTRACT

Parkinson's disease (PD) is the most common movement disorder in Europe, affecting more than two million people between 50 and 70 years of age. The current therapeutic approaches are of symptomatic nature and fail to halt the progressive neurodegenerative course of the disease. The development of innovative and complementary approaches to promote cellular repair may pave the way for disease-modifying therapies which may lead to less suffering for the patients and their families and finally to more cost-effective therapies. To date, cell replacement trials in PD aiming at replacing lost dopamine neurons were mainly focused on placing the transplanted cells within the target site, the striatum, and not within the lesioned site, the substantia nigra (SN). This was based on the misconception that the adult brain constitutes a non-permissive barrier not allowing the outgrowth of long distance axons originating from transplanted embryonic neurons. A growing body of evidence is challenging this concept and proposing instead to place the graft within its ontogenic site. This has been performed in several lesional animal models for various traumatic or neurodegenerative pathologies of the brain. For instance, transplanted neurons within the lesioned motor cortex were shown to be able to send distant and appropriate projections to target areas including the spinal cord. Similarly, in an animal model of PD, mesencephalic embryonic cells transplanted within the lesioned SN send massive projections to the striatum and, to a lesser extent, the frontal cortex and the nucleus accumbens. This has lead to the proposal that homotopic transplantation may be an alternative in cell-based therapies as transplanted neurons can integrate within the host brain, send projections to target areas, restore the damaged circuitry, increase neurotransmitter levels and ameliorate behavior. We will discuss also the potential of replacing embryonic neuronal cells by stem cell derived neurons as the use of embryonic cells is not without an ethical and logistical burden; in this line many have thrived to derive neurons from embryonic stem cells (ESC) in order to use them for cell transplantation. These studies are already yielding important information for future approaches in the field of cell therapies in PD but also in other neurodegenerative disorders where cell transplantation therapy may be considered. While the field of cell replacement therapies has been recently called into question with contrasting results in transplanted PD patients, these new sets of findings are raising new hopes and opening new avenues in this rejuvenated field.


Subject(s)
Brain/pathology , Cell Transplantation/methods , Parkinson Disease/pathology , Parkinson Disease/therapy , Adult , Animals , Behavior/physiology , Corpus Striatum/pathology , Corpus Striatum/transplantation , Humans , Nerve Degeneration/pathology , Nerve Degeneration/therapy , Nerve Net/pathology , Substantia Nigra/pathology , Substantia Nigra/transplantation
5.
J Physiol ; 591(1): 77-91, 2013 Jan 01.
Article in English | MEDLINE | ID: mdl-23045338

ABSTRACT

Cell replacement therapy for Parkinson's disease has predominantly focused on ectopic transplantation of fetal dopamine (DA) neurons into the striatum as a means to restore neurotransmission, rather than homotopic grafts into the site of cell loss, which would require extensive axonal growth. However, ectopic grafts fail to restore important aspects of DA circuitry necessary for controlled basal ganglia output, and this may underlie the suboptimal and variable functional outcomes in patients. We recently showed that DA neurons in homotopic allografts of embryonic ventral mesencephalon (VM) can send long axonal projections along the nigrostriatal pathway in order to innervate forebrain targets, although the extent of striatal reinnervation remains substantially less than can be achieved with ectopic placement directly into the striatal target. Here, we examined the possible benefits of using younger VM donor tissue and over-expression of glial cell-derived neurotrophic factor (GDNF) in the striatal target to improve the degree of striatal innervation from homotopic grafts. Younger donor tissue, collected on embryonic day (E)10, generated 4-fold larger grafts with greater striatal targeting, compared to grafts generated from more conventional E12 donor VM. Over-expression of GDNF in the host brain also significantly increased DA axonal growth and striatal innervation. Furthermore, a notable increase in the number and proportion of A9 DA neurons, essential for functional recovery, was observed in younger donor grafts treated with GDNF. Behavioural testing confirmed functional integration of younger donor tissue and demonstrated that improved motor function could be attributed to both local midbrain and striatal innervation. Together, these findings suggest there is significant scope for further development of intra-nigral grafting as a restorative approach for Parkinson's disease.


Subject(s)
Fetal Tissue Transplantation , Parkinson Disease/therapy , Substantia Nigra/transplantation , Animals , Cell Transplantation , Corpus Striatum/physiology , Disease Models, Animal , Female , Mice , Neural Pathways
6.
Prog Brain Res ; 200: 113-42, 2012.
Article in English | MEDLINE | ID: mdl-23195417

ABSTRACT

Parkinson's disease (PD) has long been considered predominantly to be a "movement disorder," and it is only relatively recently that nonmotor symptoms of PD have been recognized to be a major concern to patients. Consequently, there has been surprisingly little investigation into the feasibility of utilizing cell replacement therapies to ameliorate any of the nonmotor dysfunctions of PD. In this chapter, we identify nonmotor impairments associated predominately with dopaminergic dysmodulation, evaluate the few emerging studies that have identified a role for dopamine and nigral transplantation in nonmotor performance, and consider a number of outstanding questions and considerations dominating the field of nigral transplantation today. Preliminary results obtained from rodent models of PD, despite being limited in number, give clear indications of graft effects on striatal processing beyond the simple activation of motor output and promise a major, exciting, and fruitful new avenue of research for the next decade. We can now consider the prospect of rewriting the opportunities for treating patients, with new stem cell sources to be complemented by new targets for therapeutic benefit.


Subject(s)
Motor Activity/physiology , Parkinson Disease/surgery , Recovery of Function/physiology , Substantia Nigra/physiology , Substantia Nigra/transplantation , Animals , Disease Models, Animal , Humans
7.
Prog Brain Res ; 200: 279-301, 2012.
Article in English | MEDLINE | ID: mdl-23195424

ABSTRACT

Neural transplantation holds the promise for restoring behavioral function following brain injury. Substantial evidence indicates that fetal neurons transplanted to the adult brain survive and incorporate into remaining neural tissue and produce positive behavioral effects. A yet-unanswered question is whether the integration of new tissue can restore complex neural circuits that connect the neocortex, basal ganglia, and brainstem, and restore functions that are mediated by these circuits. This chapter describes the skilled reaching task, a task that requires transport of the arm and hand to grasp a food item and withdrawal to place the food item in the mouth for eating. It is a movement that is readily expressed in rodents and is fundamental to both nonhuman primates and humans. Methods for analyzing skilled reaching have been developed for preclinical rodent and mouse models of Parkinson's disease and Huntington's disease that are generalizable to humans with those clinical disorders. It is suggested that the task provides a motor benchmark for assessing the restoration of function produced by neural transplantation.


Subject(s)
Cell Transplantation/physiology , Corpus Striatum/cytology , Motor Skills Disorders/surgery , Motor Skills/physiology , Substantia Nigra/cytology , Animals , Corpus Striatum/transplantation , Disease Models, Animal , Humans , Huntington Disease/complications , Mice , Motor Skills Disorders/etiology , Parkinson Disease/complications , Substantia Nigra/transplantation
8.
Prog Brain Res ; 200: 199-220, 2012.
Article in English | MEDLINE | ID: mdl-23195420

ABSTRACT

In vivo functional imaging has provided objective evidence for the integration and function of nigral grafts in the brains of patients with Parkinson's disease. Clinical trials with the use of positron emission tomography have shown that transplants of human dopamine-rich fetal ventral mesencephalic tissue can survive, grow, and release dopamine providing motor symptom relief, and also that they can restore brain activation related to movement. Positron emission tomography has aided in the elucidation of the pathophysiology of serious adverse effects, so-called graft-induced dyskinesias. With the use of newly established radioligands, positron emission tomography and single-photon emission computed tomography could help to improve Parkinson's patient selection in future clinical trials by selecting those with better predicted outcomes. Moreover, positron emission tomography could help monitoring postoperational inflammatory processes around the grafted tissue and the effect of immunosuppression. Recent evidence from positron emission tomography has provided insight of how ongoing extrastriatal serotonergic denervation may have relevance to nonmotor symptoms in transplanted Parkinson's disease patients indicating new cell therapy targets for a more complete relief of symptoms. Functional and structural magnetic resonance imaging techniques could help to better assess the integration of nigral graft with the host brain by assessing the restoration of brain activation during movement and of functional and structural connectivity. This knowledge should lead to the development of new, optimized in vivo imaging protocols that could help to better schedule, monitor, and modify the clinical outcomes of future human trials assessing the efficacy of fetal or stem cell therapy in Parkinson's disease.


Subject(s)
Brain Tissue Transplantation/methods , Clinical Trials as Topic , Neuroimaging , Parkinson Disease/diagnosis , Substantia Nigra/physiology , Clinical Trials as Topic/instrumentation , Clinical Trials as Topic/methods , Humans , Parkinson Disease/surgery , Substantia Nigra/transplantation
9.
Exp Neurol ; 236(1): 58-68, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22524988

ABSTRACT

Clinical trials have provided proof of principle that new dopamine neurons isolated from the developing ventral midbrain and transplanted into the denervated striatum can functionally integrate and alleviate symptoms in Parkinson's disease patients. However, extensive variability across patients has been observed, ranging from long-term motor improvement to the absence of symptomatic relief and development of dyskinesias. Heterogeneity of the donor tissue is likely to be a contributing factor in the variable outcomes. Dissections of ventral midbrain used for transplantation will variously contain progenitors for different dopamine neuron subtypes as well as different neurotransmitter phenotypes. The overall impact of the resulting graft will be determined by the functional contribution from these different cell types. The A9 substantia nigra pars compacta dopamine neurons, for example, are known to be particularly important for motor recovery in animal models. Serotonergic neurons, on the other hand, have been implicated in unwanted dyskinesias. Currently little knowledge exists on how variables such as donor age, which have not been controlled for in clinical trials, will impact on the final neuronal composition of fetal grafts. Here we performed a birth dating study to identify the time-course of neurogenesis within the various ventral midbrain dopamine subpopulations in an effort to identify A9-enriched donor tissue for transplantation. The results show that A9 neurons precede the birth of A10 ventral tegmental area dopamine neurons. Subsequent grafting of younger ventral midbrain donor tissue revealed significantly larger grafts containing more mitotic dopamine neuroblasts compared to older donor grafts. These grafts were enriched with A9 neurons and showed significantly greater innervation of the target dorso-lateral striatum and DA release. Younger donor grafts also contained significantly less serotonergic neurons. These findings demonstrate the importance of standardized methods to improve cell therapy for Parkinson's disease and have significant implications for the generation and selectivity of dopamine neurons from stem cell based sources.


Subject(s)
Brain Tissue Transplantation/methods , Dopaminergic Neurons/transplantation , Fetal Tissue Transplantation/methods , Parkinsonian Disorders/surgery , Substantia Nigra/transplantation , Animals , Brain Tissue Transplantation/pathology , Cell Differentiation/physiology , Disease Models, Animal , Dopaminergic Neurons/cytology , Dopaminergic Neurons/physiology , Female , Fetal Tissue Transplantation/pathology , Mice , Mice, Transgenic , Neurogenesis/physiology , Parkinsonian Disorders/pathology , Primary Cell Culture , Substantia Nigra/embryology , Substantia Nigra/physiology
10.
Br Med Bull ; 100: 173-89, 2011.
Article in English | MEDLINE | ID: mdl-21875864

ABSTRACT

BACKGROUND: Functional imaging provides a valuable adjunct to clinical evaluation for assessing the efficacy of cell-based restorative therapies in Parkinson's disease (PD). SOURCES OF DATA: In this article, we review the latest advances on the use of positron emission tomography (PET) imaging in evaluating the surgical outcome of embryonic dopamine (DA) cell transplantation in PD patients. AREAS OF AGREEMENT: These studies suggest long-term cell survival and clinical benefit following striatal transplantation of fetal nigral tissue in PD patients and in models of experimental parkinsonism. AREAS OF CONTROVERSY: Adverse events subsequent to transplantation have also been noted and attributed to a variety of causes. GROWING POINTS: Optimal outcomes of DA cell transplantation therapies are dependent on tissue composition and phenotype of DA neurons in the graft. AREAS TIMELY FOR DEVELOPING RESEARCH: Given continued progress in DA neuron production from stem cells in recent years, transplantation of neural stem cells may be the next to enter clinical trials in patients. CONCLUSION: The existing data from studies of embryonic DA transplantation for advanced PD have provided valuable insights for the design of new cell-based therapies for the treatment of this and related neurodegenerative disorders.


Subject(s)
Embryonic Stem Cells/transplantation , Parkinson Disease/therapy , Substantia Nigra/transplantation , Brain/diagnostic imaging , Humans , Parkinson Disease/diagnostic imaging , Positron-Emission Tomography , Stem Cell Transplantation/adverse effects , Stem Cell Transplantation/trends , Treatment Outcome
11.
Behav Brain Res ; 216(1): 129-35, 2011 Jan 01.
Article in English | MEDLINE | ID: mdl-20655334

ABSTRACT

Many Parkinson's disease (PD) patients suffer from anxiety disorders, which often precede the onset of classical motor symptoms. So far, there is no evidence from randomized, placebo-controlled trials for successful treatment of anxiety in patients with PD. Grafts of fetal nigral neurons are currently explored as a restorative cell therapy for PD. In PD animal models, intrastriatal transplantations of embryonic dopaminergic neurons have been shown to ameliorate behavioral defects. In our previous study we showed that expanded and differentiated neural progenitors improved drug-induced rotation behavior and posture balance as a more complex motor task. However, it is not clear whether grafting of these cells affected spontaneous locomotor activity and anxiety-like behavior in 6-OHDA lesioned rats. Therefore, we analyzed behavior of control, lesioned, sham-transplanted, and transplanted rats using open field (OF) and elevated plus maze (EPM). After unilateral 6-OHDA lesion of the medial forebrain bundle, we observed reduced locomotor activity in the EPM (wall-rearing, entries in closed arms) in lesioned and sham-transplanted rats, which correlated with the loss of dopaminergic neurons and apomorphine-induced rotation behavior. Furthermore, anxiety-like behavior in the EPM (entries and time in open arms) was increased in lesioned and sham-transplanted rats. Although exogenous cell replacement improved apomorphine-induced rotation behavior, locomotor activity and anxiety-like behavior was not reconstituted in transplanted rats. However, we provided evidence for an interaction of locomotor activity/anxiety-like behavior with graft localization in the host striatum. These results emphasize the crucial role of graft localization for benefit of restorative cell therapy for PD.


Subject(s)
Anxiety/physiopathology , Corpus Striatum/transplantation , Dopamine/metabolism , Medial Forebrain Bundle/physiopathology , Motor Activity/physiology , Neurons/transplantation , Substantia Nigra/transplantation , Analysis of Variance , Animals , Brain Tissue Transplantation , Corpus Striatum/embryology , Corpus Striatum/metabolism , Female , Fetal Tissue Transplantation , Immunohistochemistry , Neurons/metabolism , Random Allocation , Rats , Rats, Sprague-Dawley , Substantia Nigra/embryology , Substantia Nigra/metabolism , Tyrosine 3-Monooxygenase/metabolism
12.
J Neural Transm (Vienna) ; 117(5): 559-72, 2010 May.
Article in English | MEDLINE | ID: mdl-20349094

ABSTRACT

Transplantation of embryonic dopaminergic neurones has shown promise for the treatment of Parkinson's disease (PD), but this approach is limited by the poor survival of the transplanted cells. Exogenous dopaminergic neurotrophic factors such as growth/differentiation factor 5 (GDF5) have been found to enhance the survival of transplanted dopaminergic neurones. However, this approach is limited by the rapid degradation of such factors in vivo; thus, methods for long-term delivery of these factors are under investigation. The present study shows, using optimised lipid-mediated transfection procedures, that overexpression of GDF5 significantly improves the survival of dopaminergic neurones in cultures of embryonic day (E) 13 rat ventral mesencephalon (VM) and protects them against 6-hydroxydopamine (6-OHDA)-induced toxicity. In another experiment, E13 VM cells were transfected with GDF5 after 1 day in vitro (DIV), then transplanted into 6-OHDA-lesioned adult rat striata after 2 DIV. The survival of these E13 VM dopaminergic neurones after transfection and transplantation was as least as high as that of freshly dissected E14 VM dopaminergic neurones, demonstrating that transfection was not detrimental to these cells. Furthermore, GDF5-overexpressing E13 VM transplants significantly reduced amphetamine-induced rotational asymmetry in the lesioned rats. This study shows that lipid-mediated transfection in vitro prior to transplantation is a valid approach for the introduction of neurotrophic proteins such as GDF5, as well as lending further support to the potential use of GDF5 in neuroprotective therapy for PD.


Subject(s)
Brain Tissue Transplantation/methods , Graft Survival/genetics , Growth Differentiation Factor 5/metabolism , Parkinson Disease/surgery , Substantia Nigra/transplantation , Transfection/methods , Animals , Cell Survival/physiology , Cells, Cultured , Dopamine/metabolism , Dyskinesia, Drug-Induced/metabolism , Dyskinesia, Drug-Induced/physiopathology , Dyskinesia, Drug-Induced/surgery , Growth Differentiation Factor 5/genetics , Lipids/pharmacokinetics , Lipids/therapeutic use , Male , Movement Disorders , Oxidopamine/pharmacology , Parkinson Disease/metabolism , Parkinsonian Disorders/metabolism , Parkinsonian Disorders/surgery , Rats , Rats, Sprague-Dawley , Substantia Nigra/cytology , Substantia Nigra/metabolism , Sympatholytics/pharmacology , Treatment Outcome
13.
Ann N Y Acad Sci ; 1184: 55-67, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20146690

ABSTRACT

Although fetal nigral transplants have been shown to survive grafting into the striatum, increased [(18)F]6-fluroro-L-3,4-dihydroxyphenylalanine ((18)F-DOPA) uptake and improved motor function in open-label assessments have failed to establish any clinical benefits in double-blind, sham-controlled studies. To understand morphological and neurochemical alterations of grafted neurons, we performed postmortem analyses on six Parkinson's disease (PD) patients who had received fetal tissue transplantation 18-19 months, 4 years, and 14 years previously. These studies revealed robust neuronal survival with normal dopaminergic phenotypes in 18-month-old grafts and decreased dopamine transporter and increased cytoplasmic alpha-synuclein in 4-year-old grafts. We also found a decline of both dopamine transporter and tyrosine hydroxylase and the formation of Lewy body-like inclusions in 14-year-old grafts, which stained positive for alpha-synuclein and ubiquitin proteins. These pathological changes suggest that PD is an ongoing process that affects grafted cells in the striatum in a manner similar to how resident dopamine neurons are affected in the substantia nigra.


Subject(s)
Fetus/pathology , Lewy Bodies/pathology , Animals , Corpus Striatum/surgery , Dihydroxyphenylalanine/analogs & derivatives , Dihydroxyphenylalanine/pharmacokinetics , Dopamine Plasma Membrane Transport Proteins/metabolism , Female , Fetal Tissue Transplantation/pathology , Fluorine Radioisotopes/pharmacokinetics , Graft Survival , Humans , Isotope Labeling , Melanins/metabolism , Pregnancy , Substantia Nigra/pathology , Substantia Nigra/transplantation , alpha-Synuclein/metabolism
14.
Cell Tissue Res ; 340(1): 29-43, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20177706

ABSTRACT

Neuronal progenitor cells (NPCs) possess high potential for use in regenerative medicine. To overcome their limited mitotic competence, various immortalization strategies have been applied that allow their prolonged maintenance and expansion in vitro. Such immortalized cells can be used for the design and discovery of new cell-based therapies for neurodegenerative diseases, such as Parkinson's disease. We immortalized rat ventral mesencephalic NPCs by using SV40 large T antigen (SV40Tag). All cell clones displayed a two- to three-fold higher proliferation rate compared with the primary cells. In order to induce dopaminergic differentiation of generated cell clones, both glial-derived neurotrophic factor and di-butyryl cyclic adenosine monophosphate were applied. Treated cells were then characterized regarding the expression of dopaminergic lineage markers, differentiation of various cell populations, calcium imaging in the presence of kainate, and immunohistochemistry after intrastriatal transplantation. Treated cells displayed morphological maturation, and calcium imaging revealed neuronal properties in the presence of kainate. These cells also expressed low mRNA levels of the dopamine transporter and tyrosine hydroxylase (TH), although no TH-immunopositive neurons were found. Intrastriatal transplantation into the neurotoxin-lesioned rats did not induce further differentiation. As an alternative approach, we silenced SV40Tag with short interfering RNA, but this was not sufficient to trigger differentiation into dopaminergic neurons. Nevertheless, neuronal and glial cells were detected as shown by beta-tubulin type III and glial fibrillary acidic protein staining, respectively. SV40Tag cells are suitable for carrying out controlled genetic modifications as shown by overexpression of enhanced green fluorescence protein after efficient non-viral transfection.


Subject(s)
Cell Differentiation/physiology , Mesencephalon/transplantation , Neurogenesis/physiology , Neurons/metabolism , Stem Cell Transplantation/methods , Stem Cells/metabolism , Animals , Antigens, Polyomavirus Transforming/genetics , Biomarkers/analysis , Biomarkers/metabolism , Cell Differentiation/drug effects , Cell Line, Transformed , Cell Lineage/genetics , Cell Proliferation , Clone Cells/cytology , Clone Cells/metabolism , Corpus Striatum/cytology , Corpus Striatum/metabolism , Corpus Striatum/surgery , Dopamine/metabolism , Dopamine Plasma Membrane Transport Proteins/genetics , Genetic Vectors/genetics , Graft Survival/physiology , Mesencephalon/cytology , Mesencephalon/embryology , Nerve Growth Factors/pharmacology , Neurogenesis/drug effects , Neurons/cytology , Neurons/drug effects , RNA Interference/physiology , Rats , Rats, Sprague-Dawley , Stem Cells/cytology , Stem Cells/drug effects , Substantia Nigra/cytology , Substantia Nigra/embryology , Substantia Nigra/transplantation , Transfection/methods , Tyrosine 3-Monooxygenase/genetics
15.
Neurosurgery ; 65(4): 741-53; discussion 753, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19834380

ABSTRACT

OBJECTIVE: To physiologically repair damaged neural circuitry using neural transplantation, the donor cells must be able to differentiate into the optimal type and number of neurons for the host brain environment. They must also be capable of functional regulation by the host brain. These features are important to optimize functional outcome and to minimize side effects. In this study, the differentiation of grafted mesencephalic neuroepithelial stem cells in the normal and parkinsonian brain was assessed morphologically and behaviorally to confirm the influence of the host brain environment after neural transplantation regarding functional outcome and side effects of transplants. METHODS: Green fluorescent protein-positive mesencephalic neuroepithelial stem cells were dissected from early rat embryos and transplanted into normal (n = 20) and Parkinson's disease (PD) rat model striata (n = 30). The differentiation pattern of grafted cells was precisely monitored immunohistochemically, and the functional effects of grafted cells on behavior were assessed using an amphetamine-induced rotation test. RESULTS: The grafted cells survived in both normal and PD rat striata and differentiated into tyrosine hydroxylase-positive cells. In 8-week-old grafts, the number of tyrosine hydroxylase-positive cells was 3-fold higher in parkinsonian brains than in normal brains. The donor-derived tyrosine hydroxylase-positive cells exhibited a mature morphology with long, well-branched cell processes and large cell bodies, especially in parkinsonian brains. Also, the process lengths of these cells in parkinsonian brains were 3.4-fold longer than those in normal brains at 8 weeks after transplantation. The grafted PD rats exhibited a complete recovery from their behavioral defects, and no obvious contralateral rotation to the lesioned and grafted side suggestive of overdose supply from the graft was observed. However, the grafted normal rats did not exhibit any contralateral rotation to the grafted side suggestive of dopamine unbalance. CONCLUSION: Grafted mesencephalic neuroepithelial stem cells can differentiate into optimal neuron types in response to environmental cues and can affect the behavior of PD rats without any side effects.


Subject(s)
Brain Tissue Transplantation/methods , Cell Differentiation/physiology , Corpus Striatum/surgery , Neurons/metabolism , Parkinsonian Disorders/surgery , Stem Cell Transplantation/methods , Animals , Biomarkers/metabolism , Cell Communication/physiology , Corpus Striatum/cytology , Corpus Striatum/metabolism , Cues , Disease Models, Animal , Dopamine/metabolism , Extracellular Fluid/metabolism , Female , Graft Survival/physiology , Green Fluorescent Proteins/metabolism , Neurogenesis/physiology , Neurons/cytology , Parkinsonian Disorders/pathology , Parkinsonian Disorders/physiopathology , Rats , Rats, Wistar , Recovery of Function/physiology , Substantia Nigra/cytology , Substantia Nigra/embryology , Substantia Nigra/transplantation , Treatment Outcome , Tyrosine 3-Monooxygenase/metabolism
16.
J Neurol ; 256 Suppl 3: 310-6, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19711122

ABSTRACT

Postmortem analyses from clinical neural transplantation trials of several subjects with Parkinson's disease revealed surviving grafted dopaminergic neurons after more than a decade. A subset of these subjects displayed isolated dopaminergic neurons within the grafts that contained Lewy body-like structures. In this review, we discuss why this isolated cell damage is unlikely to affect the overall graft function and how we can use these observations to help us to understand age-related neurodegeneration and refine our future cell replacement therapies.


Subject(s)
Brain Tissue Transplantation/methods , Graft Survival/physiology , Nerve Degeneration/physiopathology , Parkinson Disease/physiopathology , Parkinson Disease/surgery , Cell Culture Techniques , Fetal Tissue Transplantation/methods , Humans , Lewy Bodies/metabolism , Lewy Bodies/pathology , Nerve Degeneration/pathology , Parkinson Disease/pathology , Substantia Nigra/transplantation , Treatment Outcome
17.
Exp Neurol ; 219(1): 341-54, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19555687

ABSTRACT

Protocols used for generation of mesencephalic dopamine (mesDA) neurons from stem cells, or fetal brain tissue, invariably result in cell preparations that are highly mixed in composition, containing mesDA neuron precursors in various states of fate commitment and differentiation. For further optimisation and refinement of these procedures it is essential to determine the optimal stage of development and phenotypic characteristics of cells used for grafting. We have used fluorescence-activated cell sorting procedures to isolate mesDA precursors in defined stages of differentiation from mouse ventral mesencephalon (VM), at embryonic day 10.5 (E10.5), when the mesDA neuron domain consists of proliferative radial glia-like cells expressing the mesDA neuron determinant Lmx1a and the floorplate marker Corin, and at E12.5, when the VM has expanded to comprise a mixture of proliferative progenitors, neuroblasts and young neurons. The sorted cells were transplanted to the striatum of 6-hydroxydopamine-lesioned rats. Results show that the Lmx1a/Corin-expressing ventricular zone progenitors, which are the source of mesDA neurons in grafts from E10.5 VM, had lost this capacity at E12.5. At this later stage all transplantable mesDA precursors resided in the intermediate zone as postmitotic Nurr1-expressing neuroblasts. The more differentiated, TH-expressing cells survived sorting and transplantation poorly. We also provide evidence that, during early mesDA neurogenesis, the progenitors for nigral mesDA neurons segregate to lateral parts of the Lmx1a-expressing domain and can be selectively isolated based on their level of Corin expression. These results have implications for current efforts to develop well-characterized stem cell-derived mesDA progenitor cell preparations for cell therapy.


Subject(s)
Brain Tissue Transplantation/methods , Mesencephalon/embryology , Mesencephalon/transplantation , Parkinsonian Disorders/surgery , Stem Cell Transplantation/methods , Stem Cells/cytology , Animals , Biomarkers/analysis , Biomarkers/metabolism , Cell Differentiation/physiology , Cells, Cultured , DNA-Binding Proteins/analysis , DNA-Binding Proteins/metabolism , Disease Models, Animal , Dopamine/metabolism , Female , Flow Cytometry/methods , Gene Knock-In Techniques , Homeodomain Proteins/analysis , Homeodomain Proteins/metabolism , LIM-Homeodomain Proteins , Mesencephalon/cytology , Mice , Mice, Transgenic , Neurogenesis/physiology , Neurons/cytology , Neurons/metabolism , Nuclear Receptor Subfamily 4, Group A, Member 2 , Parkinsonian Disorders/metabolism , Parkinsonian Disorders/physiopathology , Rats , Serine Endopeptidases/analysis , Serine Endopeptidases/metabolism , Stem Cells/metabolism , Substantia Nigra/cytology , Substantia Nigra/embryology , Substantia Nigra/transplantation , Transcription Factors/analysis , Transcription Factors/metabolism , Tyrosine 3-Monooxygenase/analysis , Tyrosine 3-Monooxygenase/metabolism
18.
J Comp Neurol ; 515(1): 31-40, 2009 Jul 01.
Article in English | MEDLINE | ID: mdl-19399891

ABSTRACT

In spite of partial success in treating Parkinson's disease by using ectopically placed grafts of dopamine-producing cells, restoration of the original neuroanatomical circuits, if possible, might work better. Previous evidence of normal anatomic projections from ventral mesencephalic (VM) grafts placed in the substantia nigra (SN) has been limited to neonatal rodents and double grafting or bridging procedures. This study attempted to determine whether injection of a potent growth-promoting factor, glial cell line-derived neurotrophic factor (GDNF), into the target regions or placement of fetal striatal co-grafts in the nigrostriatal pathway might elicit neuritic outgrowth to the caudate nucleus. Four adult St. Kitts green monkeys received embryonic VM grafts into the rostral mesencephalon near the host SN, and injections of adeno-associated virus 2 (AAV2)/GDNF or equine infectious anemia virus (EIAV)/GDNF into the caudate. Three adult monkeys were co-grafted with fetal VM tissue near the SN and fetal striatal grafts (STR) 2.5 mm rostral in the nigrostriatal pathway. Before sacrifice, the striatal target regions were injected with the retrograde tracer Fluoro-Gold (FG). FG label was found in tyrosine hydroxylase-labeled neurons in VM grafts in the SN of only those monkeys that received AAV2/GDNF vector injections into the ipsilateral striatum. All monkeys showed FG labeling in the host SN when FG labeling was injected on the same side. These data show that grafted dopaminergic neurons can extend neurites to a distant target releasing an elevated concentration of GDNF, and suggest that grafted neurons can be placed into appropriate loci for potential tract reconstruction.


Subject(s)
Brain Tissue Transplantation/methods , Corpus Striatum/metabolism , Embryonic Stem Cells/transplantation , Glial Cell Line-Derived Neurotrophic Factor/metabolism , Stem Cell Transplantation/methods , Substantia Nigra/transplantation , Animals , Cell Differentiation/physiology , Cells, Cultured , Chlorocebus aethiops , Corpus Striatum/cytology , Corpus Striatum/physiopathology , Disease Models, Animal , Graft Survival/physiology , Growth Cones/metabolism , Growth Cones/ultrastructure , Male , Neural Pathways/cytology , Neural Pathways/metabolism , Neurites/metabolism , Neurites/ultrastructure , Parkinsonian Disorders/metabolism , Parkinsonian Disorders/physiopathology , Parkinsonian Disorders/surgery , Staining and Labeling , Stilbamidines , Substantia Nigra/cytology , Substantia Nigra/metabolism , Treatment Outcome , Up-Regulation/physiology
19.
J Comp Neurol ; 515(1): 41-55, 2009 Jul 01.
Article in English | MEDLINE | ID: mdl-19399892

ABSTRACT

The functional restorative capacity of fetal dopaminergic (DA) transplants is governed by a number of critical parameters including graft location, survival of DA neurons, and transplantation technique. In addition, there is an ongoing controversy whether "too much" or "too little" survival of DA neurons is responsible for the incomplete functional recovery observed in some transplanted Parkinson's disease (PD) patients. Here we investigated two implantation sites, the nucleus accumbens (NAc) and the caudate-putamen unit (CPU), and two different graft distributions within the CPU, i.e., two 0.75 microL deposits (CPU-2) versus six 0.25 microL deposits (CPU-6) in a rat model of PD. Grafts were derived from E14 rat ventral mesencephalon and the long-term functional outcome was evaluated with a wide range of complex-sensorimotor behavioral tests. The data show that forelimb stepping, balancing behavior, and skilled forelimb reaching behavior was more restored in CPU-6-grafted animals as compared to CPU-2 animals, although the number surviving dopaminergic neurons and dopamine release were similar in the two groups. Furthermore, a correlation analysis revealed a number of inverse relationships between the rate of DA neuron survival and sensorimotor performances, e.g., for skilled forelimb use. DA grafts placed into the NAc induced a partial recovery in drug-induced rotation tests but failed to restore any of the other sensorimotor behaviors tested. Taken together, these data have important implications both for a better understanding of the complex functional graft-host interactions as well as for the further optimization of clinical neural transplantation strategies in neurodegenerative diseases.


Subject(s)
Brain Tissue Transplantation/methods , Corpus Striatum/surgery , Parkinsonian Disorders/surgery , Recovery of Function/physiology , Stem Cell Transplantation/methods , Substantia Nigra/transplantation , Animals , Cell Differentiation/physiology , Cells, Cultured , Corpus Striatum/metabolism , Corpus Striatum/physiopathology , Disease Models, Animal , Dopamine/metabolism , Female , Lameness, Animal/metabolism , Lameness, Animal/physiopathology , Lameness, Animal/surgery , Motor Skills/physiology , Nerve Regeneration/physiology , Neuronal Plasticity/physiology , Neurons/cytology , Neurons/metabolism , Neurons/transplantation , Nucleus Accumbens/metabolism , Nucleus Accumbens/physiopathology , Nucleus Accumbens/surgery , Parkinsonian Disorders/metabolism , Parkinsonian Disorders/physiopathology , Rats , Rats, Sprague-Dawley , Substantia Nigra/cytology , Substantia Nigra/metabolism , Time , Treatment Outcome
20.
J Comp Neurol ; 515(1): 72-82, 2009 Jul 01.
Article in English | MEDLINE | ID: mdl-19399894

ABSTRACT

Supplementation of antioxidants to the diet has been proved to be beneficial in aging and after brain injury. Furthermore, it has been postulated that the locus coeruleus promotes survival of dopamine neurons. Thus, this study was performed to elucidate the effects of a blueberry-enriched diet on fetal ventral mesencephalic tissue in the presence or absence of locus coeruleus utilizing the in oculo grafting method. Sprague-Dawley rats were given control diet or diet supplemented with 2% blueberries, and solid tissue pieces of fetal locus coeruleus and ventral mesencephalon were implanted as single and co-grafts. The results revealed that the presence of locus coeruleus tissue or the addition of blueberries enhanced the survival of ventral mesencephalic tyrosine hydroxylase (TH)-positive neurons, whereas no additive effects were observed for the two treatments. The density of TH-positive nerve fibers in ventral mesencephalic tissue was significantly elevated when it was attached to the locus coeruleus or by blueberry treatment, whereas the innervation of dopamine-beta-hydroxylase-positive nerve fibers was not altered. The presence of locus coeruleus tissue or bluberry supplementation reduced the number of Iba-1-positive microglia in the ventral mesencephalic portion of single and co-grafts, respectively, whereas almost no OX6 immunoreactivity was found. Furthermore, neither the attachment of ventral mesencephalic tissue nor the addition of blueberries improved the survival of TH-positive neurons in the locus coerulean grafts. To conclude, locus coeruleus and blueberries are beneficial for the survival of fetal ventral mesencephalic tissue, findings that could be useful when grafting tissue in Parkinson's disease.


Subject(s)
Antioxidants/pharmacology , Brain Tissue Transplantation/methods , Graft Survival/physiology , Mesencephalon/transplantation , Neurons/metabolism , Stem Cell Transplantation/methods , Animals , Antioxidants/therapeutic use , Axons/drug effects , Axons/metabolism , Axons/ultrastructure , Blueberry Plants/chemistry , Cell Communication/drug effects , Cell Communication/physiology , Cell Differentiation/drug effects , Cell Differentiation/physiology , Dopamine/biosynthesis , Female , Food, Formulated , Graft Survival/drug effects , Locus Coeruleus/drug effects , Locus Coeruleus/metabolism , Locus Coeruleus/transplantation , Mesencephalon/drug effects , Mesencephalon/metabolism , Neurons/cytology , Neurons/drug effects , Ophthalmologic Surgical Procedures/methods , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Rats , Rats, Sprague-Dawley , Substantia Nigra/drug effects , Substantia Nigra/metabolism , Substantia Nigra/transplantation , Treatment Outcome , Tyrosine 3-Monooxygenase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...